Immunitybio vs Karyopharm Therapeutics
Karyopharm Therapeutics is the larger business, with $146m of revenue in fiscal 2025 against $113m for Immunitybio (1.3 times as much). Immunitybio grew faster (668.3% against 0.6%). Karyopharm Therapeutics kept more of each dollar of sales as profit: a net margin of -134.2% against -310.2%.
| Latest fiscal year | ImmunitybioIBRX, 2025 | Karyopharm TherapeuticsKPTI, 2025 |
|---|---|---|
| Revenue | $113m | $146m |
| Revenue growth | 668.3% | 0.6% |
| Net income | −$351m | −$196m |
| Operating margin | -226.0% | -62.1% |
| Net margin | -310.2% | -134.2% |
| Return on equity | — | — |
| Free cash flow | −$309m | −$75.4m |
| Cash | $88.3m | $60.5m |
| Total debt | $326m | $94.8m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 691 | 228 |
| Market value | $8.69bn | $2.0m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 16 sales | 0 buys, 21 sales |